Section
Compounding
503A and 503B pharmacies, shortages and telehealth supply.
- 08:58PEPTI
PEPTI publishes pharmacy certificates of analysis on quality page
- Sep 16The Manila Times
MEDVi Swaps PT-141 for Apomorphine in 2026 QUAD Formula
Third Texas peptide compounder hit with recall, watchdog reports
- Sep 16newswire.com
MEDVi swaps PT-141 for apomorphine in compounded ED formula
By Maren Holt - Sep 16Johns Hopkins University
Johns Hopkins examines the compounding problem in peptide therapies
- Sep 15USA Today
USA Today Guides Patients on Vetting Compounded GLP-1 Sellers
Safe Medicines Group Warns of Compounded GLP-1 Crisis
- Sep 15Endpoints News
Centric Compounding Recalls Three Injectable Products Over Contamination
- Sep 15PEPTI
PEPTI prices its BPC-157 and TB-500 recovery protocol at $259 a month
By Maren Holt - Sep 14San Antonio Express-News
Another Texas pharmacy recalls injectable peptides over fatal risk
- Sep 14tipranks.com
CurifyLabs targets US compounding pharmacy growth at industry events
By Maren Holt - Sep 14PlexusDx
PlexusDx ranks 50 compounded tirzepatide providers by true cost
- Sep 12PEPTI
PEPTI lays out what 2026 compounding rules mean for peptide patients
By Maren Holt - Sep 12Pulse 2.0
Quva acquires CAPS 503B sterile compounding product portfolio
By Maren Holt - Sep 11Pharmacy Times
Pharmacy Times: USP standards gain weight as peptides go mainstream
By Maren Holt - Sep 10Mealey's
Judge trims Eli Lilly conspiracy claims in compounded tirzepatide suit